Business Context and Reporting Period
This Form 8-K was filed by Aileron Therapeutics, Inc. (not Rein Therapeutics, Inc.) on November 10, 2022. The report details a material corporate action regarding the company's capital structure.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure adjustment.
Material Changes
- Reverse Stock Split: Effective November 10, 2022, at 5:00 p.m. Eastern Time, the company executed a 1-for-20 reverse stock split of its common stock.
- Share Conversion: Every 20 shares of outstanding common stock were converted into one share. No fractional shares were issued; instead, stockholders entitled to fractional shares received a proportional cash payment.
- Authorized Shares: The authorized number of common shares was reduced from 300,000,000 to 15,000,000 and subsequently multiplied by three, resulting in 45,000,000 authorized shares.
- Adjustments: All outstanding stock options and warrants were adjusted in accordance with their terms.
- Trading: Trading on a reverse stock split-adjusted basis commenced on the Nasdaq Capital Market on November 11, 2022.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the summary is qualified by the full text of the Certificate of Amendment.
Investor Verification Checklist
- Verify the adjusted share count and price per share on the Nasdaq Capital Market effective November 11, 2022.
- Confirm the adjustment ratios applied to any outstanding stock options or warrants held.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for complete legal terms.
- Note that the company is an emerging growth company.